Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naïve Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study

“…23,38,39 However, no differences were observed between Dolutegravir and Darunavir in the FLAMINGO and SYMTRI randomized trials. 41,42 A recent collaborative cohort showed a more favourable immunologic response, defined as 25% increase in CD4 count or as reaching ≥750 cells/mL at one year, with INSTI-vs PI-or NNRTI-based regimens. 40 This study, however, included both treatment-na€ ıve and treatment-experienced individuals, did not assess the effect of INSTI on long-term mortality nor the specific effect on immune responses in the subpopulation of LP, and residual confounding could not be fully excluded.…”